Key result
Pre-eclampsia features suppressed circulating RAS components but upregulated local placental RAS signaling and AT1 autoantibodies.
This review highlights that differential regulation between the downregulated systemic circulating RAS and the upregulated local uteroplacental RAS (particularly elevated placental Ang II, AT1 receptor expression, and AT1 autoantibodies) plays a central role in the pathophysiology of pre-eclampsia.
Answers are grounded in this paper and cite their sources.
May caution against systemic RAS modulation in pre-eclampsia; leaves open placental AT1-targeted therapies for prospective trials.
Pregnancy is characterized by an increase in many of the different components of the circulating renin-angiotensin system (RAS). However, the physiological mechanisms of stimulated RAS activity during pregnancy are unknown. Even less understood is how this system may be altered in pre-eclampsia, a hypertensive disorder of pregnancy. Additional studies have shown the presence of a local tissue specific RAS in the uteroplacental unit of normal and pre-eclamptic pregnancies. Differences in normal pregnant and pre-eclamptic RAS component regulation may provide insight into the mechanisms responsible for the clinical pathological features of pre-eclampsia. Specifically, this review summarizes the key findings in the circulating and uteroplacental RAS in normal and pre-eclamptic pregnancies.
No takes yet. Share an insight, caveat, or question.
Anton et al. (2008) conducted a review in Pre-eclampsia and normal pregnancy. Pre-eclampsia / Altered renin-angiotensin system (RAS) regulation vs. Normal normotensive pregnancy was evaluated on Systemic and uteroplacental renin-angiotensin system (RAS) component expression and regulation.
Synapse has enriched 10 related papers. Consider them for comparative context: